Evidence map›Paper›PMID 35203521›Full record

ReviewBiomedicines2022

Radiosensitization and Radioprotection by Curcumin in Glioblastoma and Other Cancers.

Vasiliki Zoi, Vasiliki Galani, Pericles Tsekeris, Athanasios P Kyritsis, George A Alexiou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Chinese herbal medicines · 2025
    Review
  13. Ampelopsis japonica enhances the effect of radiotherapy in non-small cell lung cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vasiliki ZoiNeurosurgical Institute, University of Ioannina, 45500 Ioannina, Greece.
Vasiliki GalaniDepartment of Anatomy Histology-Embryology, School of Medicine, University of Ioannina, 45110 Ioannina, Greece.
Pericles TsekerisDepartment of Radiation Oncology, University of Ioannina, 45110 Ioannina, Greece.
Athanasios P KyritsisNeurosurgical Institute, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0003-0370-1024
George A AlexiouNeurosurgical Institute, University of Ioannina, 45500 Ioannina, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation therapy plays an important role in almost every cancer treatment. However, radiation toxicity to normal tissues, mainly due to the generation of reactive free radicals, has limited the efficacy of radiotherapy in clinical practice. Curcumin has been reported to possess significant antitumor properties. Although curcumin can sensitize cancer cells to irradiation, healthy cells are much less sensitive to this effect, and thus, curcumin is thought to be a potent, yet safe anti-cancer agent. In this review, a summary of the role of curcumin as both a radiosensitizer and radioprotector has been presented, based on the most recent data from the experimental and clinical evaluation of curcumin in different cancer cell lines, animal models, and human patients.

Indexed as

cancercurcuminradiation therapyradiosensitizer

Identifiers

PMID35203521
PMCPMC8869399

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.